A Phase 1 Study of CAR T Cell Therapy for People with HIV and B Cell Lymphoma

Full Title

Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma (AMC-112) (CIRB)

Purpose

This study is assessing axicabtagene clioleucel CAR T cell therapy for people with HIV-related aggressive B cell lymphoma. The people in this study have B cell non-Hodgkin lymphoma that has come back or keeps growing after treatment, including:

• Diffuse large B cell lymphoma
• High-grade B cell lymphoma
• Primary mediastinal B cell lymphoma
• Follicular lymphoma grade 3B

T cells are immune cells that can kill tumor cells. Axicabtagene ciloleucel is made of genetically modified T cells that were altered in a lab to recognize CD19. The CD19 protein is on the surface of B cell cancer cells. 

Axicabtagene ciloleucel is given once intravenously (by vein). You will also get cyclophosphamide and fludarabine to prepare your body for the CAR T cell therapy.

Contact

For more information or to see if you can join this study, please call Dr. M. Lia Palomba’s office at 646-608-3711.